Search research articles
Contact Us
Filters
Showing results (51-60 of 65) with videos related to
Page
of 7
Sort By:
Oncotarget
|
December 10, 2016
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
Costantine Albany, Mary P Hever-Jardine, Katherine M von Herrmann, et al.
The Journal of Urology
|
January 10, 2016
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration
Patrizia Giannatempo, Gregory R Pond, Guru Sonpavde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2015
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group
Darren R Feldman, Anja Lorch, Andrew Kramar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Christopher J Sweeney, Ivor J Percent, Sunil Babu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 27, 2019
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
Stefanie Fischer, Torgrim Tandstad, Gabriella Cohn-Cedermark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2017
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm
Torgrim Tandstad, Christian K Kollmannsberger, Bruce J Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 21, 2017
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer
Emmanuel S Antonarakis, Scott T Tagawa, Giuseppe Galletti, et al.
European Urology
|
December 18, 2017
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
Matthew D Galsky, Huan Wang, Noah M Hahn, et al.
JCO Precision Oncology
|
November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer
Fadi Taza, Albert E Holler, Wei Fu, et al.
Clinical Genitourinary Cancer
|
January 2, 2017
Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy
Derek E Thomas, Hristos Z Kaimakliotis, Kevin R Rice, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 65) with videos related to
Sort By:
Page
of 7
Oncotarget
|
December 10, 2016
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
Costantine Albany, Mary P Hever-Jardine, Katherine M von Herrmann, et al.
The Journal of Urology
|
January 10, 2016
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration
Patrizia Giannatempo, Gregory R Pond, Guru Sonpavde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2015
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group
Darren R Feldman, Anja Lorch, Andrew Kramar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Christopher J Sweeney, Ivor J Percent, Sunil Babu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 27, 2019
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
Stefanie Fischer, Torgrim Tandstad, Gabriella Cohn-Cedermark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2017
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm
Torgrim Tandstad, Christian K Kollmannsberger, Bruce J Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 21, 2017
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer
Emmanuel S Antonarakis, Scott T Tagawa, Giuseppe Galletti, et al.
European Urology
|
December 18, 2017
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
Matthew D Galsky, Huan Wang, Noah M Hahn, et al.
JCO Precision Oncology
|
November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer
Fadi Taza, Albert E Holler, Wei Fu, et al.
Clinical Genitourinary Cancer
|
January 2, 2017
Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy
Derek E Thomas, Hristos Z Kaimakliotis, Kevin R Rice, et al.
Page
of 7